Back to today’s briefing

Story perspectives

Novo Nordisk Drops Lawsuit, Hims & Hers Launches Ozempic and Wegovy

3/9/2026

44 6 Full Breakdown

Summary

Story summary

Novo Nordisk dropped patent infringement lawsuit against Hims & Hers, enabling telehealth provider to sell Ozempic and Wegovy.
Hims will offer oral and injectable versions starting later this month.
The agreement followed Hims' plan to launch a cheaper version of Wegovy, which prompted Novo Nordisk to sue.
Hims agreed to stop advertising compounded GLP-1 drugs.
Hims shares rose over 40% after the announcement and Novo retains the option to refile.

History

Historical Context

The Patent Act of 1952 established a comprehensive framework for patent protection in the U.S., introducing significant changes such as the requirement for non-obviousness. This legislation has influenced pharmaceutical companies like Novo Nordisk, which recently dropped a lawsuit against Hims & Hers over drug formulations, highlighting ongoing tensions in the industry regarding medication access and pricing strategies.

1 of 2

Story summary

Novo Nordisk dropped patent infringement lawsuit against Hims & Hers, enabling telehealth provider to sell Ozempic and Wegovy.
Hims will offer oral and injectable versions starting later this month.
The agreement followed Hims' plan to launch a cheaper version of Wegovy, which prompted Novo Nordisk to sue.
Hims agreed to stop advertising compounded GLP-1 drugs.
Hims shares rose over 40% after the announcement and Novo retains the option to refile.

1 / 2